Re: Cornerstone License Agreement dated August 31, 2006, as amended - Second Amendment

Exhibit 10.14

Cornerstone Biopharma, Inc.

February 15, 2008

Allan M. Weinstein, M.D.
Pharmaceutical Innovations, LLC
3301 New Mexico Avenue, N.W., Suite 302
Washington, D.C. 20016

Re: Cornerstone License Agreement dated August 31, 2006, as amended — Second Amendment

Dear Allan:

This letter will serve to reflect our agreement regarding an amendment of the above-referenced license agreement (the “Agreement”). As you know, Cornerstone Biopharma, Inc. (“Cornerstone”) exercised its right under Section 6.03 of the Agreement to terminate the Agreement with respect to the Licensed Product referenced in Section 1.10(ii) (Allerx HC) by providing written notice to Pharmaceutical Innovations, LLC on December 22, 2007 of such intent. The parties wish to amend the Agreement to reflect such partial termination as well as make other modifications to the Agreement.

Section 1.10 of the Agreement is hereby deleted in its entirety and replaced with the following.

“1.10. Licensed Products” shall mean the following prescription day-night products which fall within the scope of one or more valid claims of any PI Patent: (i) a product (which may be known as AlleRx PE) consisting of 40 mg. phenylephrine/2.5 mg. methscopolamine nitrate, for daytime use and 10 mg. phenylephrine/8 mg. chlorpheniramine maleate/2.5 mg. methscopolamine nitrate for nighttime use; and (ii) a product consisting of 120 mg. pseudoephedrine/2.5 mg. methscopolamine nitrate, for daytime use and 8 mg. chlorpheniramine maleate/2.5 mg. methscopolamine nitrate/an attenuated dose of pseudoephedrine or phenylephrine for nighttime use.

Section 4.03 of the Agreement is hereby deleted in its entirety and replaced with the following:

“4.03 With respect to the Licensed Products referenced in Section 1.10 hereof, Cornerstone shall pay to PI Minimum Royalty Payments equal to Three Hundred Thousand Dollars ($300,000) per Calendar Year for the term of this Agreement beginning with Calendar Year 2007 and ending at the beginning of the Seven Year Period (such Minimum Royalty Payments to be pro rated for periods of less than twelve months); provided, however, that the Minimum Royalty Payments for Calendar Year 2007 shall be One Hundred Fifty Thousand Dollars ($150,000). To clarify regarding pro

ration, by way of example, if the PI Patents expire on August 31, 2011, the Minimum Royalty Payment for that Calendar Year shall be 66 2/3% of $300,000 or $200,000.”

Please sign where indicated below to confirm that this letter constitutes the Second Amendment to the Agreement and that Sections 1.10 and 4.03 now read as shown above.